I would add that CYDY's chances of selling much PRO 140 in the combo therapy (salvage) market is not high. Since treatment experienced patients are the only ones in that market, most are R4. So, PRO 140 is ineffective for most patients in that market. They will have trouble finding a partner offering them attractive terms to market PRO 140 in the salvage market because of this. This is no doubt why management focus is now more on the monotherapy market since most newer HIV patients are R5, for which PRO 140 is effective. Monotherapy is also a much bigger market, so that is hopeful, but it will take the company a lot of time and money it does not presently have to get monotherapy approved. If they can find the money, I would not be surprised if it did get approved.
Also, I would point out a partnership is also dilutive as CYDY would have to exchange some of the revenues from the drug with whomever they were partnering with. The number of shares would not increase in a partnership but the revenues received per share would.
Finally, the amount of money needed to get to monotherapy approval is likely going to prove greater than they suggested. That amount was just to get the current trial completed. Also, the full amount of money needed will be greater than $60 million since the CFO also said they will need some unspecified amount of funds to cover SG&A costs too.
I have to believe some way will be found to get PRO 140 on the market but I can't really say it will be in a manner that will help current shareholders.
News 
Market Data 
Discover 
